Novavax (NVAX) – Novavax, an American vaccine development company headquartered in Gaithersburg, Maryland, announced today that they are planning to launch trials in humans of their experimental coronavirus vaccine in Australia. Novavax expects the initial results from the study in July to come in around July of this year. Novavax says if the trials are deemed a success, they will expand the trials into the United States.
This study begins with the enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373. Stanley C. Erck, President and Chief Executive Officer of Novavax, said “Administering our vaccine in the first participants of this clinical trial is a significant achievement, bringing us one step closer toward addressing the fundamental need for a vaccine in the fight against the global COVID‑19 pandemic,” and “We look forward to sharing the clinical results in July and, if promising, quickly initiating the Phase 2 portion of the trial.”
Novavax has identified their NVX‑CoV2373 vaccine as its lead SARS-CoV-2 candidate following some testing that showed the vaccine had high immunogenicity and high levels of neutralizing antibodies.
For more information and updates on this be sure to check back at the ABN Blog.